Evidence map›Paper›PMID 30882001›Full record

ArticleBioMed research international2019

Tyrosine Kinase Inhibitor Imatinib Mesylate Alters DMBA-Induced Early Onco/Suppressor Gene Expression with Tissue-Specificity in Mice.

Péter Attila Gergely, Balázs Murnyák, János Bencze, Andrea Kurucz, Timea Varjas, Katalin Gombos, Tibor Hortobágyi

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BioMed research international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Imatinib Sets Pericyte Mosaic in the Retina.International journal of molecular sciences · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Péter Attila GergelyInstitute of Forensic Medicine, University of Debrecen, 4012 Debrecen, Hungary.ORCID 0000-0002-0437-4072
Balázs MurnyákMTA-DE Cerebrovascular and Neurodegenerative Research Group, Department of Neurology, University of Debrecen, 4012 Debrecen, Hungary.ORCID 0000-0002-8500-7951
János BenczeInstitute of Pathology, Faculty of Medicine, University of Debrecen, 4012 Debrecen, Hungary.ORCID 0000-0002-6357-0671
Andrea KuruczDepartment of Pharmacology and Pharmacotherapy, University of Debrecen, 4012 Debrecen, Hungary.
Timea VarjasDepartment of Public Health Medicine, Medical School, University of Pécs, 7624 Pécs, Hungary.ORCID 0000-0002-4950-0669
Katalin GombosDepartment of Laboratory Medicine, Clinical Center, University of Pécs, 7624 Pécs, Hungary.
Tibor HortobágyiMTA-DE Cerebrovascular and Neurodegenerative Research Group, Department of Neurology, University of Debrecen, 4012 Debrecen, Hungary.ORCID 0000-0001-5732-7942
University of Debrecen · HUUniversity of Pecs · HU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tyrosine kinases play crucial roles in cellular development and tumorigenesis. Tyrosine kinase inhibitors (TKIs) are effective and widely used drug molecules in targeted cancer therapies. Altered expressions of protooncogenes and tumor suppressor genes after DMBA (7,12-dimethylbenz[a]anthracene) treatment have been described as early markers of tumor induction; however their tissue-specific effects remain still unclear. Our study was aimed at examining the short-term possible antineoplastic and chemopreventive effects of a TKI compound (imatinib mesylate) on a DMBA-induced mouse tumor model. In addition, we also investigated the tissue-specific expressions of

Indexed as

AnimalsAnthracenesAnticarcinogenic AgentsGene Expression Regulation, NeoplasticHumansImatinib MesylateMiceNeoplasmsOrgan SpecificityPiperidinesProtein Kinase InhibitorsProto-Oncogene Proteins c-mycProto-Oncogene Proteins p21(ras)Tumor Suppressor Protein p533-(2,6-bis(4-fluorophenyl)-3-methylpiperidin-4-ylideneamino)-2-thioxoimidazolidin-4-one on 7,12-dimethylbenz(a)anthraceneAnthracenesAnticarcinogenic AgentsHRAS protein, humanImatinib MesylateKRAS protein, humanPiperidinesProtein Kinase InhibitorsProto-Oncogene Proteins c-mycProto-Oncogene Proteins p21(ras)Trp53 protein, mouseTumor Suppressor Protein p53

Identifiers

PMID30882001
PMCPMC6383434
OpenAlexW2911742195

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.